• Only four of 97 new medicines or indications rated by Prescrire in 2010 provided any therapeutic advantage. (Revue Prescrire, 2011)

Health Action International’s staff and network have unparalleled expertise in all areas of pharmaceutical policy, including intellectual property, pharmaceutical R&D, free trade, pharmaceutical marketing, clinical trial data transparency and pharmaceutical pricing.

To arrange an interview, or book them to speak at an event, please contact our media team.